• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CollabRx, University of Chicago collaborate

CollabRx, University of Chicago collaborate

June 19, 2013
CenterWatch Staff

CollabRx data analytics, focused on informing clinical decision making in molecular medicine, is collaborating with the thoracic oncology program at the University of Chicago Medical Center, a cancer treatment center with clinical and translational research programs in cancer genetics and therapeutics.

The initiative will combine CollabRx content and technology resources with the results of genetic sequencing-based tests conducted at the medical center. The tests are designed to enable physicians to consider a tumor's unique genetic profile in cancer treatment planning.

"This commitment includes consideration of drugs and other therapies that target genetic abnormalities in tumors,” said Ravi Salgia, M.D., Ph.D., vice chair of translational research at the University of Chicago and collaboration leader. “These genetic abnormalities can now be efficiently identified using cancer mutation panels based on next generation sequencing technologies. CollabRx's systems add substantial value to these panels by infusing interpretation and insight from recognized thought leaders who have knowledge of the latest scientific and medical research in molecular oncology and, more importantly, understand how to apply this knowledge to inform treatment planning at the point of care.”

CollabRx will provide a turnkey medical informatics solution by pairing the results of cancer mutational panels conducted by Salgia and colleagues at the medical center with clinically actionable and dynamically updated knowledge provided by CollabRx. Such knowledge includes the clinical impact of specific mutational profiles and associated therapeutic strategies such as drugs and clinical trials. It also is supported by CollabRx's network of over 75 experts and clinical practitioners in the U.S. and Europe.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing